Abstract
Migraine prophylaxis 2019 - the role of CGRP antagonists Abstract. The CGRP System is part of the pain pathway within the complex pathophysiology of migraine. Monoclonal antibodies targeting the CGRP system are the first class of substances developed specifically for the prevention of migraine, i. e. the reduction of attack frequency and intensity. The efficacy of this class of substances is comparable to established anti-migraine prophylactic medication. Tolerability and safety seem excellent in the published studies as well as in our clinical experience up to now. Limitations for reimbursement are expected for all substances within this class due to a relatively high price as compared to established drugs. The first substance in class is on the market in Switzerland. The role, these substances will play in the stratified treatment of sufferers will have to be established in clinical practice after several of these monoclonal antibodies will be on the market.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
